J&J's Win Upheld In Antibody Patent Fight Against Abbott

Law360, New York (March 11, 2013, 1:59 PM EDT) -- A Massachusetts federal judge on Friday upheld a jury's verdict that found two antibody patents held by Abbott GmbH & Co. KG were invalid, finalizing a courtroom win for Johnson & Johnson subsidiary Janssen Biotech Inc.

U.S. District Judge F. Dennis Saylor rejected various post-trial motions filed by Abbott, which had accused Janssen of infringing the two patents by selling the psoriasis treatment Stelara. The decision means the jury's September verdict that both patents were invalid will be entered as final judgment.

Abbott had asked for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.